Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab
Authors
Keywords
-
Journal
NATURE BIOTECHNOLOGY
Volume 29, Issue 7, Pages 615-624
Publisher
Springer Nature
Online
2011-07-12
DOI
10.1038/nbt.1903
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis
- (2011) Y.W. Zhu et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans
- (2011) Paola Di Meglio et al. PLoS One
- Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells
- (2010) Valérie Staudt et al. IMMUNITY
- Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters
- (2010) Manjula REDDY et al. JOURNAL OF DERMATOLOGY
- Oesophageal squamous cell carcinoma in a young adult with IL-12R 1 deficiency
- (2010) M. Cardenes et al. JOURNAL OF MEDICAL GENETICS
- Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab
- (2010) Jinquan Luo et al. JOURNAL OF MOLECULAR BIOLOGY
- Effector T cell plasticity: flexibility in the face of changing circumstances
- (2010) Kenneth M Murphy et al. NATURE IMMUNOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comorbidities in Patients with Psoriasis
- (2009) Alice B. Gottlieb et al. AMERICAN JOURNAL OF MEDICINE
- Risk-based strategy for the assessment of pharmacokinetic drug–drug interactions for therapeutic monoclonal antibodies
- (2009) Honghui Zhou et al. DRUG DISCOVERY TODAY
- Plasticity of CD4+ T Cell Lineage Differentiation
- (2009) Liang Zhou et al. IMMUNITY
- Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis
- (2009) Yaowei Zhu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis
- (2009) Honghui Zhou et al. JOURNAL OF CLINICAL PHARMACOLOGY
- IL-23 Promotes the Production of IL-17 by Antigen-Specific CD8 T Cells in the Absence of IL-12 and Type-I Interferons
- (2009) M. M. Curtis et al. JOURNAL OF IMMUNOLOGY
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells
- (2009) Sara Trifari et al. NATURE IMMUNOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12
- (2008) D. van de Wetering et al. INTERNATIONAL IMMUNOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now